By targeting immune checkpoints, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1)/PD-ligand 1 (PD-L1), ICIs have elicited durable responses and survival gains across multiple tumor types (2–4). This evidence concerns the gene CTLA4 and neoplasm.